---
title: Biomarkers
date: '2025-01-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39785355/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250109170938&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: In addition to accurately screening for A+ individuals,
  plasma p217+tau shows promise for separating persons with either Intermediate or
  Advanced stage AD from those at a lower stage, providing prognostic information
  and informing better selection for trials and disease modifying ...'
disable_comments: true
---
CONCLUSION: In addition to accurately screening for A+ individuals, plasma p217+tau shows promise for separating persons with either Intermediate or Advanced stage AD from those at a lower stage, providing prognostic information and informing better selection for trials and disease modifying ...